|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-12-15
|
|
pubmed:abstractText |
A 2-year prospective, partially randomized open-label trial comparing oral alendronate with intravenous pamidronate therapy in children with OI showed equivalence in increasing total body BMD, spine BMD, and linear growth, and decreasing bone turnover and fracture incidence. Children with mild OI had greater responses than severe OI in BMD and growth.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0884-0431
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
132-40
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16355282-Administration, Oral,
pubmed-meshheading:16355282-Alendronate,
pubmed-meshheading:16355282-Biological Markers,
pubmed-meshheading:16355282-Bone Density Conservation Agents,
pubmed-meshheading:16355282-Bone Remodeling,
pubmed-meshheading:16355282-Child,
pubmed-meshheading:16355282-Diphosphonates,
pubmed-meshheading:16355282-Female,
pubmed-meshheading:16355282-Fractures, Bone,
pubmed-meshheading:16355282-Humans,
pubmed-meshheading:16355282-Incidence,
pubmed-meshheading:16355282-Injections, Intravenous,
pubmed-meshheading:16355282-Male,
pubmed-meshheading:16355282-Osteogenesis Imperfecta,
pubmed-meshheading:16355282-Prospective Studies
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
|
|
pubmed:affiliation |
Department of Pediatrics, Section of Pediatric Endocrinology and Diabetology, Indiana University School of Medicine, Indianapolis, Indiana, USA. dimeglio@iupui.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
